Table 3 BAX mRNA expression and NPC patients’ survival

Univariate analysis

BAX mRNA expression

 Negative

1.00

1.00

 Positive

0.28

0.13 – 0.62

0.001

0.27

0.12 – 0.59

0.001

Gender (male / female)

1.42

0.66 – 3.09

0.37

1.81

0.79 – 4.18

0.16

Age (≤ 30 years / >30 years)

1.51

0.61 – 3.73

0.37

1.82

0.68 – 4.84

0.23

Tumor histology (undifferentiated / non-keratinizing)

0.59

0.28 – 1.25

0.17

0.72

0.33 – 1.57

0.41

Tumor extent (ordinal)

1.46

1.01 – 2.13

0.046

1.52

1.03 – 2.23

0.034

Regional lymph node status (ordinal)

1.34

0.91 – 1.98

0.14

1.32

0.90 – 1.94

0.16

TNM stage (ordinal)

2.79

1.82 – 4.26

<0.001

1.81

1.31 – 2.48

<0.001

Multivariate analysis

BAX mRNA expression^c

 Negative

1.00

1.00

 Positive

0.35

0.15 – 0.86

0.022

0.33

0.13 – 0.84

0.020

Gender (male / female)

1.26

0.48 – 3.31

0.64

1.66

0.55 – 4.99

0.37

Age (≤ 30 years / >30 years)

1.45

0.53 – 4.01

0.47

1.88

0.59 – 5.95

0.28

Tumor histology (undifferentiated / non-keratinizing)

0.64

0.30 – 1.40

0.27

0.61

0.26 – 1.40

0.24

Tumor extent (ordinal)

1.26

0.76 – 2.06

0.37

1.34

0.79 – 2.29

0.27

Regional lymph node status (ordinal)

1.06

0.70 – 1.60

0.78

1.07

0.68 – 1.70

0.77

BAX mRNA expression^d

 Negative

1.00

1.00

 Positive

0.67

0.29 – 1.56

0.35

0.36

0.16 – 0.84

0.018

Gender (male / female)

0.78

0.35 – 1.76

0.55

1.20

0.46 – 3.08

0.71

Age (≤ 30 years / >30 years)

1.68

0.66 – 4.31

0.28

2.18

0.76 – 6.24

0.15

Histology (undifferentiated / non-keratinizing)

0.95

0.43 – 2.12

0.90

0.64

0.27 – 1.50

0.30

TNM stage

2.60

1.68 – 4.04

<0.001

1.76

1.25 – 2.46

0.001